Approach to patients with eosinophilia

Lanny J Rosenwasser, Lanny J Rosenwasser

Abstract

Eosinophilia is commonly seen in medical practice and can underlie a variety of medical conditions. Eosinophilia, defined as peripheral blood eosinophil counts greater than 500 per microliter, may vary from mild-severe. Idiopathic hypereosinophilic syndrome has been identified as an unusual cause of moderate to severe eosinophilia. Progress in treatment of this condition has accompanied greater understanding about the basic biology of eosinophils. This review will highlight the approach to patients with eosinophilia, along with associated conditions and syndromes.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6188379/bin/ms108_p0358f1.jpg

References

    1. Valent P. Pathogenesis, classification, and therapy of eosinophilia and eosinophilic disorders. Blood Rev. 2009;23:157–65.
    1. Rothenberg ME, Hogan SP. The eosinophils. Ann Rev Immunol. 2006:147–74.
    1. Sanderson CJ. Interleukin-5, eosinophils and disease. Blood. 1992;79:3101–9.
    1. Simon D, Simon HU. Eosinophilic disorders. J Allergy Clin Immunol. 2007;119:1291–300.
    1. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol. 2010;124:242–5.
    1. Chusid MJ, Dale CD, West BC, Wolff SM. The hypereosinophilic syndrome analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975;54:1–27.
    1. Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358:1215–28.
    1. Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009;124:1319–25.
    1. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl Med. 2003;348:1201–14.
    1. Rosenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. 2010;125(6):1245–6.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren